Skip to content
You are now leaving https://www.ionispharma.com to visit

Ionis Innovation

Grants & Sponsorships

Click on the tabs below to learn more about each of the different grant programs with IONIS, qualifications and requirements for each, and deadlines for submissions.

Janice Wiesman Young Investigator Grant Program Ionis Young Investigator Grant Program Independent Medical Education Grants

Janice Wiesman Young Investigator Grant Program

Objective

The objective of the Janice Wiesman Young Investigator Grant Program is to provide funding to researchers at eligible academic or nonprofit institutions who submit innovative research proposals in the areas of translational, clinical, or applied research. The research should advance the understanding of ATTR amyloidosis, facilitate early diagnosis of patients with ATTR amyloidosis, and/or enhance management of patients with a diagnosis of ATTR amyloidosis. Specifically, this program will support two young investigators, such as current fellows, residents, or junior faculty, annually to promote quality research related to ATTR amyloidosis and to support the development of future researchers and clinicians.

Overview

Ionis’s Young Investigator Grant Program is named in honor of Dr. Janice Wiesman (1958-2020), a world expert on the neurological impact of amyloidosis who demonstrated remarkable commitment to and advancement of the field. This award will be granted on a competitive basis for a maximum of two academic years. The first year of the award is guaranteed, while the second year is contingent upon submission and approval of a progress report demonstrating both advancement towards the proposed research objectives and ongoing research. Applications for the Young Investigator Grant Program must be submitted in writing and will be reviewed by the review committee comprised of Medical Affairs and Compliance personnel. Applications will be assessed based on the scientific merit of the proposed research and the scientific qualifications of the applicant.

Deadlines and Important Dates
  • Application Deadline – April 1, 2023
    Late submissions or incomplete applications will not be considered.
  • Award Notification – May 2, 2023
    Award recipients and their affiliated institutions receive award notification.
  • Acceptance Deadline – July 15, 2023
    Grant agreement must be fully executed to receive grant funding.
Young Investigator Grant Funds

The Young Investigator Grant funds will be paid directly to the investigator’s institution.
Grant awards will be funded in the amount of $50,000 per year and may be renewable for a second year at the same level, provided sufficient progress has been made towards the research objectives and with approval of a submission demonstrating progress and ongoing research.

The award may be transferred to another investigator if needed, upon renewal of the second year and after approval from Ionis. The transfer of the award to another investigator requires review and approval by the review committee to confirm the new investigator meets all the eligibility requirements and is qualified to continue the ongoing research.
The grant funds may only be used as described in the awarded proposal submission. The award may not be used for promotional purposes or to advance the nonscientific interests of Ionis, the investigator, or the investigator’s institution.

The investigator’s institution is not limited in the amount of additional support it may provide to the investigator.
Submissions duplicative of other research or focused on competitor products are ineligible for the Young Investigator Grant Program.

Eligibility and Qualifications
  • Mentors may submit the application on behalf of an investigator if the investigator has not yet been identified.
  • Investigator must hold a doctorate degree during the grant period.
  • Investigator may not have more than 3 years of postdoctoral research experience.
  • Investigator must be employed on a full-time basis and must be currently in training in the areas of translational, clinical, or applied research. Investigators may be residents, fellows, or junior faculty.
  • Investigators with existing tenure-track research positions or senior faculty appointments are ineligible.
  • Investigator must not be excluded from participation in any government healthcare program and must not be otherwise ineligible for participation in federal healthcare programs.
  • Investigator must be either a United States citizen or in possession of a valid permit or visa as follows:
    • Green Card (permanent residency visa, unlimited duration, can lead to US citizenship)
    • H1B Visa (the primary US work visa for professionals and students from all over the world or in the USA who work in specialty occupations, valid for up to 6 years, a dual intent visa; those with an H1B4 Visa can also apply for permanent residency)
    • E3 Visa (similar to the H1B but only available to Australian citizens)
    • TN1 Visa (similar to the H1B but available only to citizens of Canada and Mexico)
    • J1 Visa (must be valid until January 2026)
Young Investigator Program Requirements
  • Funded research must be conducted in an academic or nonprofit institution.
  • The awarded grant should broaden the postdoctoral research experience of the young investigator and not be used for further support of preexisting and extensive postdoctoral research training.
  • Funded research must be conducted under the supervision of an experienced mentor at the sponsoring institution.
  • Proposed research must have an anticipated completion timeline of 2 years or less.
  • The awarded grant cannot be transferred to an alternate investigator or institution in the event the original institution and investigator dissolve their association without approval by Ionis.
  • Ionis Medical Affairs must be immediately notified, in writing and with appropriate justification, if the sponsoring institution anticipates any delay of the term.
  • Ionis expects investigators to publish the results of all completed research, irrespective of study outcome. Ionis may request an opportunity to review any disclosure (including abstracts, posters, presentations, and manuscripts) that results from the awarded grant, for purposes of preventing inadvertent disclosure of Ionis proprietary information and addressing any factual inaccuracies. Ionis may request a short delay in publication if necessary, to protect intellectual property rights.
  • In granting a Young Investigator Grant, no preference shall be given to reward, induce, or in exchange for recommending, prescribing, dispensing, purchasing, supplying, selling, administering, referring, arranging for, or ordering Ionis products. A Young Investigator recipient is never expected or obliged to recommend, prescribe, dispense, purchase, supply, sell, administer, refer, arrange for, or order Ionis products.
Application Materials

The following must be submitted via email to [email protected] to apply:

1. Grant Award Request Letter
Must be on institutional letterhead, written and signed by the Department Chair, Division Chief, or Training Program Director and must include:

  • Academic term dates for investigator’s current position if applicable (e.g., June 1, 2023, to June 30, 2024)
  • Statement of:
    • Mentor’s qualifications to supervise and train the investigator
    • Scientific prowess of the institution
    • Institutional commitment to advancing the care of patients with ATTR amyloidosis

2. Current Curriculum Vitae or NIH Biosketch

Mentor (required)
Investigator (required if known)

3. Research Proposal (preferably not to exceed 5 pages)
Proposal to include:

  • Introduction, research objectives, and rationale
  • Background and significance
  • Specific area of research
  • Preliminary data (if available)
  • Design and methods (including statistical analyses)
  • Patient population
  • Investigator’s role in design and execution of research proposal
  • Detailed budget, including other funding sources (if applicable)
  • References

4. Letter of Support from Mentor

  • Detail the eligibility, scientific skills, and background of the investigator and how the award would be beneficial for the development of this young investigator.

OR, if investigator is not yet identified:

  • Describe the selection process for identifying an investigator to complete the funded research and how the award would be beneficial at his/her institution for developing a young investigator.

5. Formal Brochure/Overview of Training Program or Department

 

Contact Information

For general questions about the Janice Wiesman Young Investigator Grant Program, please contact us at [email protected]

Ionis logo                   Astra Zeneca logo

Ionis Young Investigator Grant Program

What is the Ionis Young Investigator Grant?

Ionis Pharmaceuticals is pleased to announce the Ionis Young Investigator Grant (YIG). This grant was recently created by the division of CardioRenal-Metabolism within Medical Affairs to recognize early career investigators who are performing high quality research in the field of severe hypertriglyceridemia. Ionis values developing clinicians and scientists who will influence the field and support new research for years to come.

Who is Eligible?

The Ionis YIG is a grant aimed at providing research grants to fellows who are at eligible academic or non-profit institutions and submit innovative research proposals in the areas of translational, clinical, or applied research. The Ionis YIG encourages early stage scientific investigators of promise to apply, who are engaged in cutting-edge research on the topic of severe hypertriglyceridemia for the following categories:

  • Clinical investigations
  • Basic and Translational Science
  • Outcomes Research (and/or EMR-related research)

The goals of the research application should focus on understanding the effects of chylomicron and/or triglyceride elevations on cardiovascular and metabolic disease. Specifically, the grant will support 2 fellows, residents, or junior faculty annually to promote quality research and support the development of future researchers and clinicians.

Overview

This grant is awarded by an independent review committee on a competitive basis for a maximum of two academic years with the first year guaranteed and the second-year contingent on approval of a progress submission demonstrating progress towards the pre-stated research objectives and ongoing research.

Deadlines and Important Dates Based on Grant Program Approval

  • Application Deadline – April 1, 2023
    Late submissions or incomplete applications will not be considered.
  • Award notification – May 2, 2023
    Grant recipients and their affiliated institutions receive grant notification.
  • Acceptance Deadline – July 15, 2023
    Grant acceptance must be signed by investigator, mentor, and institution and returned to receive grant funds.
Young Investigator Grant Funds
  • The Young Investigator Grant will be paid directly to the grantee’s institution
  • Grant will be funded in the amount of $50,000 per year and may be renewable for a second year at the same level provided sufficient progress has been made towards the research objectives and with approval of a progress submission demonstrating progress and ongoing research
  • The grant may be transferred to another investigator if needed upon renewal for the second year after approval from Ionis (ex. after completion of 1-year fellowship)
  • Grant may only be used as described in the granted proposal submission
  • Institution is not limited in the amount of additional support it may provide the investigator
  • Submissions duplicative of other research, prior submissions of Investigator sponsored studies, or projects focused on competitor products are not eligible for the Young Investigator Grant Program
Applicant Eligibility and Qualifications 
  • Mentors may submit the application on behalf of the investigator if not yet selected; this will allow the institution to know if funding has been secured to support a fellowship position in advance
  • Investigator must hold a doctorate degree during the grant period
  • Investigator may not have more than 3 years of post-doctoral research experience
  • Investigators working full-time and currently in training are eligible to apply, including residents
  • Applicants with existing tenure-track research positions or senior faculty appointments are ineligible
  • Investigator must be either a United States citizen, in possession of a current student visa or a permanent alien resident, specifically:
    • US Citizen
    • Green Card – permanent residency visa – unlimited duration, can lead to US Citizenship
    • H1B Visa – the primary US Work Visa for professionals & students from all over the world or in the USA, who work in specialty occupations. Valid up to 6 years, dual intent visa (can apply for Green Card)
    • E3 Visa – similar to the H1B but is available to Australian Citizens only
    • TN1 Visa – similar to the H1B but is available to Canadian & Mexican Citizens only
    • J1 Visa (must be valid until January 2026)
Young Investigator Program Requirements
  • Funded research must be conducted in an academic or non-profit institution
  • Grant should broaden the postdoctoral research experience of the young investigator and not be used for further support of preexisting and extensive postdoctoral research training
  • Funded research must be conducted under the supervision of an experienced mentor at the sponsoring institution
  • Proposed research must have anticipated completion timeline of 2 years or less
  • The grant cannot be transferred to an alternate investigator or institution in the event the original institution and investigator dissolve their association without approval by Ionis
  • Ionis Medical Affairs must be notified, in writing with appropriate justification, immediately if the sponsoring institution anticipates any delay of the term
  • Expected Outcomes: submission of data for external presentation and/or publication within 2 years of initial funding
Application Materials

The following must be submitted via email to [email protected] to apply:

  1. Grant Request Letter
    Must be on institutional letterhead, written and signed by the Department Chair, Division Chief or Training Program Director and include:
  • Academic term dates for investigator’s current position if applicable (e.g., July 1, 2023 to June 30, 2025)
  • Statement of:
    • mentor’s qualifications to supervise and train the investigator
    • scientific prowess of the institution
    • institutional commitment to advancing the care of patients with cardiology or metabolic disease
  1. Current Curriculum Vitae or NIH Biosketch
  • Mentor (required)
  • Investigator (required if known)
  1. Research Proposal (preferably not to exceed 5 pages)
    Proposal to include:
  • Introduction, research objectives and rationale
  • Background and significance
  • Specific area of research
  • Preliminary data (if available)
  • Design and methods (including statistical analyses)
  • Patient population
  • Investigator’s role in design and execution of research proposal
  • Detailed budget, including other funding sources (if applicable)
  • References
  1. Letter of Support from Mentor
  • Detail the eligibility, scientific skills, and background of the investigator and how the grant would be beneficial for the development of this young investigator

OR, if investigator not yet identified,

  • Describe the selection process for identifying an investigator to complete the funded research and how the grant would be beneficial at his/her institution for developing a young investigator
  1. Formal brochure/overview of training program or department
Contact Information

For more information, please contact Ionis Medical Affairs at [email protected].

Ionis Logo

Independent Medical Education Grants

Overview

Ionis recognizes the importance of Independent Medical Education (IME) and is committed to supporting programs that enhance patient care. Ionis supports targeted high-quality accredited and non-accredited medical education programs to advance excellence in healthcare by improving disease awareness, clinical knowledge, and multidisciplinary management within our therapeutic areas of focus.

 

Areas of Focus

We are accepting grant applications for medical education programs within the United States for the following therapeutic areas:

Hereditary Angioedema:

  • Current treatment challenges, unmet needs of patients, and investigational drugs in late-stage development for this rare disease.

Severe Hypertriglyceridemia including genetic conditions such as Familial Chylomicronemia Syndrome:

  • Pathophysiology, disease burden, and management of elevated triglycerides.
  • Current treatment challenges, unmet needs of patient, and investigational drugs in late-stage development.
Grant Submission Process

All IME grants will be submitted through our Grant portal. Please log in here to submit your request.

Typical turnaround times for funding decisions are between 30 and 60 days from the date of submission of the IME grant application.

Required information and documentation

  • Letter of request on letterhead with signature from requestor addressed to the Ionis Medical Education Grant Review Committee detailing unmet educational needs and practice gaps
  • Date, location, venue, or platform of activity
  • Description of program
  • Type of accreditation (if any)
  • Number and type of credit hours to be issued for program completion
  • Intended target audience and estimated participation
  • Amount of funding requested and purpose of funding
  • Sole-support or multi-supported activity
  • Statement that budgets will be reconciled within 90 days and unused funds will be returned
  • Detailed agenda including all program topics and faculty (if available)
  • Detailed budget including a breakdown of how requested funds will be spent
  • W-9
Contact Info

For questions about the Ionis’ IME grant program or the grant portal, please contact us at [email protected].

 

Please note that Global and United States IME grants requests for amyloid transthyretin cardiomyopathy (ATTR-CM) and amyloid transthyretin polyneuropathy (ATTR-PM) will now be submitted to and reviewed by our global development and commercialization partner AstraZeneca. Please visit www.astrazenecagrants.com to review the application procedure and/or to submit.